Select a medication above to begin.
azacitidine
generic
Adult Dosing .
Dosage forms: INJ
Special Note
- [formulation clarification]
- Info: do not substitute for PO azacitidine
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses, premeds, and dosing incl. toxicity-related dose adjustments
myelodysplastic syndrome
- [75-100 mg/m^2/dose SC/IV x1 on days 1-7 of 28-day cycle]
- Start: 75 mg/m^2/dose SC/IV x1 on days 1-7 of 28-day cycle for cycle 1 and 2; Info: give for at least 4-6 cycles
AML, newly diagnosed (off-label)
- [combo w/ ivosidenib; IDH1-mutated dz]
- Dose: 75 mg/m^2/dose SC/IV x1 on days 1-7 of 28-day cycle for at least 6mo; Alt: 75 mg/m^2/dose SC/IV x1 on days 1-5 and 8-9 of 28-day cycle for at least 6mo; Info: for pts 75 yo and older, or who are ineligible for intensive induction chemo d/t comorbidities
- [combo w/ venetoclax]
- Dose: 75 mg/m^2/dose SC/IV x1 on days 1-7 of 28-day cycle; Info: for pts 75 yo and older, or who are ineligible for intensive induction chemo d/t comorbidities; cytoreduction may be required if WBC >25,000 prior to 1st dose
renal dosing
- [see below]
- CrCl >30: no adjustment; CrCl <30: not defined, caution advised
- HD/PD: not defined
hepatic dosing
- [see below]
- hepatic dz: not defined, caution advised; advanced malignant hepatic tumors: contraindicated
Peds Dosing .
- Dosage forms: INJ
Special Note
- [formulation clarification]
- Info: do not substitute for PO azacitidine
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses, premeds, and dosing incl. toxicity-related dose adjustments
juvenile myelomonocytic leukemia
- [1 mo-11 mo or <10 kg]
- Dose: 2.5 mg/kg/dose IV x1 on days 1-7 of 28-day cycle; Max: 6 cycles; Info: give for at least 3 cycles; D/C if ANC <500 at end of cycle 3 or on day 1 of cycles 5 or 6
- [1 yo and older and >10 kg]
- Dose: 75 mg/m^2/dose IV x1 on days 1-7 of 28-day cycle; Max: 6 cycles; Info: give for at least 3 cycles; D/C if ANC <500 at end of cycle 3 or on day 1 of cycles 5 or 6
renal dosing
- [see below]
- CrCl >30: no adjustment; CrCl <30: not defined, caution advised
- HD/PD: not defined
hepatic dosing
- [see below]
- hepatic dz: not defined, caution advised; advanced malignant hepatic tumors: contraindicated